<DOC>
	<DOCNO>NCT01732718</DOCNO>
	<brief_summary>The purpose research study learn effect drug , atorvastatin , blood vessel patient sickle cell disease . The primary hypothesis endothelial dysfunction important contributor pathophysiology albuminuria SCD . The investigator propose atorvastatin improve endothelial dysfunction , decrease level sFLT-1 , decrease albuminuria SCD patient . Participants individual sickle cell disease , age 18 60 , degree albuminuria . A total 19 subject , male female , enrol . The study make Screening , Treatment , Follow Up phase cross-over design . After patient screened eligibility , randomize receive atorvastatin placebo initial six-week treatment period . When complete , four-week washout period begin another six-week treatment period . In second treatment period , `` cross-over '' treatment arm . Four week end second treatment period , follow-up safety assessment do .</brief_summary>
	<brief_title>Effect Atorvastatin Endothelial Dysfunction Albuminuria Sickle Cell Disease</brief_title>
	<detailed_description>It well recognize sickle cell disease ( SCD ) characterize vasculopathy , involvement multiple organ include brain , lung , spleen , kidney . This result multiple clinical complication , include ischemic stroke , pulmonary hypertension , autosplenectomy , well albuminuria chronic renal disease . Several recent study confirm association albuminuria renal dysfunction echocardiographically-defined pulmonary hypertension vasculopathic complication SCD , suggest may share similar pathophysiology . Despite high prevalence albuminuria patient SCD know association renal failure increase mortality , pathophysiology treatment albuminuria set remain poorly define . The treatment option nephropathy SCD limit . Although ACE inhibitor `` standard care '' treatment patient proteinuria , date control , long-term study confirm efficacy safety set . In study , investigator evaluate efficacy safety atorvastatin SCD patient . At completion trial , investigator improve understanding contribution endothelial dysfunction pathophysiology albuminuria SCD . If data support hypothesis atorvastatin safe effective population , investigator plan carry adequately power study definitively evaluate safety efficacy treatment and/or prevention albuminuria SCD .</detailed_description>
	<mesh_term>Kidney Diseases</mesh_term>
	<mesh_term>Anemia , Sickle Cell</mesh_term>
	<mesh_term>Albuminuria</mesh_term>
	<mesh_term>Atorvastatin Calcium</mesh_term>
	<criteria>1 . Sickle cell anemia ( HbSS ) Sicklebeta0 thalassemia ( HbSbeta0thal ) age 18 60 ; 2. albuminuria ( micro macroalbuminuria , define =/ &gt; 30mg/g creatinine ) ; 3. serum alanine aminotransferase ( ALT ) and/or GGT &lt; /= 2 time upper limit normal ; 4. platelet count &gt; 150,000 cu/mm ; 5. normal baseline coagulation profile ( PT , International Normalized Ratio ( INR ) , PTT ) ; 6. noncrisis , steady state severe pain episode precede 4 week , document infection 2 week prior enrollment ; 7. ability understand requirement study ; 8. woman childbearing potential , must use adequate method contraception ; 9. receive hydroxyurea , ACE inhibitor angiotensin blocker ( ARB ) , stable dose least 3 month . 1. hypersensitivity component atorvastatin , history adverse reaction statin ; 2. pregnant breastfeeding ; 3. statin therapy ; 4. history metastatic cancer ; 5. current history alcohol abuse ; 6. history diabetes mellitus poorly control systemic hypertension ; 7. endstage renal disease ; 8. total cholesterol level &lt; 80 mg/dL LDL cholesterol &gt; 130 mg/dL ; 9. chronic transfusion program ; 10. ingest investigational drug within past 4 week ; 11. prior history myopathy ; 12. allergy nitroglycerin ; 13. take follow drug : phosphodiesterase5 inhibitor ( e.g. , sildenafil ) , cytochrome P450 isoenzyme 3A4 ( CYP3A4 ) inhibitor ( e.g. , cyclosporine , protease inhibitor ) , macrolide antibiotic ( e.g. , clarithromycin , erythromycin ) , fibric acid derivative ( e.g . gemfibrozil ) , niacin , colchicine , antifungal agent ( azole derivative ) , amiodarone , danazol , daptomycin , diltiazem , verapamil , eltrombopag , everolimus , fosphenytoin , lanthanum . Patients also encourage avoid grape fruit juice red yeast rice duration study . Atorvastatin contraindicate pregnancy breastfeeding .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>60 Years</maximum_age>
	<verification_date>November 2016</verification_date>
	<keyword>sickle cell disease</keyword>
	<keyword>endothelial function</keyword>
	<keyword>albuminuria</keyword>
	<keyword>atorvastatin</keyword>
	<keyword>soluble fms-like tyrosine kinase-1</keyword>
</DOC>